Five year collaboration agreement on real world evidence

Published 2016-11-22 15:30. Updated 2018-02-26 13:02Denna sida på svenska

KI has closed a five year collaboration agreement with MSD on real world evidence. The collaboration will be managed by the Department of Epidemiology and Biostatistics and will give KI a financial support of 1 million USD per year for five years.

In 2014, KI and MSD (Merck and Co. Inc. in US, MSD in Sweden) signed a non-binding Letter of Intent to express a mutual intention to engage in a strategic collaboration. The focus for the collaboration is to build knowledge and expertise through the use of real world data across broad population segments, to help inform future medical and clinical research, product development and economic models.

This week, KI and MSD signed a Master Collaboration Agreement to establish the framework and governance structure for the future collaboration projects. The therapeutic areas in focus include cardiovascular disease, Alzheimer’s disease, diabetes, hepatitis C and cancer.

The Department of Epidemiology and Biostatistics will manage the collaboration which will be open to suitable projects anywhere at KI. The financial support is primarily provided by MSD, and will give no less than USD1 million per calendar year, for five years.

CollaborationRegister-based research